

South Carolina  
Department of Health and Human Services  
1801 Main Street  
Columbia, South Carolina 29201-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**November 6, 2024**  
MINUTES

- I. Welcome and Call to order.....Edward Behling, MD
- Called to order at 4:06pm.

*Freedom of Information Act/Americans with Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.*

- II. Roll Call ..... Kim Bristow, RPh
- Committee members were encouraged to attend future meetings in person.

**Committee Members Present:**

|                          |                         |                         |
|--------------------------|-------------------------|-------------------------|
| Edward Behling, MD       | Kelly Barth, DO         | Duncan Norton, MD       |
| Cheryl Hartvigsen, RPh   | Divya Ahuja, MD         | Heather Hembree, PharmD |
| Katherine Lewis, MD      | Garrett Whittle, PharmD | Jony Bolinger, MD       |
| Patricia Witherspoon, MD | Kimberly Rudd, MD       |                         |

**SC DHHS Staff:**

Cheryl Anderson, RPh  
Kevin Wessinger, MD  
Kim Bristow, RPh  
Brandie Crider, BSBA, CPhT  
Tawanna Zeigler, MHSA, CPhT  
Ashley Sirianni, DNP, FNP-BC  
Rhonda Smith, Esq

**PRIME:**

Blake Cook, RPh  
Manisa Bulsara, PharmD  
Lisa Correll, PharmD  
Alexis Jones, MHA, MA, CPhT

- III. Approval of Minutes from August 6, 2024..... P&T Committee
  - The draft minutes from the previous P&T Committee meeting August 6, 2024, were emailed to the members for review prior to the meeting.
    - Garrett Whittle, PharmD motioned to approve the previous P&T meeting minutes and Patricia Witherspoon, MD seconded the motion for approval. The minutes were approved unanimously.
  
- IV. Single Preferred Drug List Overview..... Blake Cook, RPh
  - Mr. Cook gave a synopsis of the single preferred drug list (sPDL) and explained where to look if changes have been made. He also provided the email addresses for questions and/or comments on the Single PDL document or process which are [SCprovidersupport@primetherapeutics.com](mailto:SCprovidersupport@primetherapeutics.com) and [SCsinglepdl@primetherapeutics.com](mailto:SCsinglepdl@primetherapeutics.com) (PDL questions).
  
- V. State Updates ..... Kevin Wessinger, MD and Kim Bristow, RPh
  - Dr. Wessinger gave an update on the sPDL launch on 7/1/24 stating so far it has been very smooth. He also reminded the committee that on 11/1/24 South Carolina Medicaid started covering injectable GLP-1 agents for weight management with prior authorization criteria. The criteria is available on the SCDHHS website. He also stated that South Carolina Medicaid is the 14<sup>th</sup> state to cover GLP-1 for weight management.
  - Mrs. Bristow notified committee members diabetic supplies are being updated on the sPDL effective on 1/1/25. Abbott blood glucose testing products are being removed from the sPDL (Freestyle and Precision Neo BG machines and test strips) and Trividia blood glucose testing products will be added as preferred to the sPDL. She also stated due to the coverage of GLP-1 medications for weight loss starting 11/1/24 and the low utilization of lipase inhibitors (Xenical/Orlistat), the state will no longer be covering lipase inhibitors for weight loss starting 1/1/25. During February’s P&T meeting, committee members will be voting on updating P&T Committee By-Laws. Details will be emailed to each committee member prior to February’s meeting.
  
- VI. Pharma Updates..... Manisa Bulsara, PharmD
  - Dr. Bulsara informed the committee that the State plans to continue utilizing the randomization process for meeting requests in 2025. There will be one 40-minute meeting per entity per year. Any questions or concerns can be directed to [scpharma@primetherapeutics.com](mailto:scpharma@primetherapeutics.com).
  
- VII. New Drugs to Market..... Manisa Bulsara, PharmD
  - Onyda XR™ (clonidine hcl)

- Tevimbra® (tislelizumab-jsgr)
- Lazcluze™ (lazertinib mesylate)
- Nemluvio™ (nemolizumab-ilto)
- Livdelzi™ (seladelpar lysine)
- Crexont™ (carbidopa/levodopa)
- Tecelra™ (afamitresgene autoleucel)
- Vigafyde™ (vigabatrin)
- Voranigo™ (vorasidenib citrate)
- Piasky™ (crovalimab-akkz)

VIII. Classes for Review..... Manisa Bulsara, PharmD

- Injectable Immunomodulators
  - Speakers:
    - Christine A. Dubé, B.S, PharmD from AstraZeneca presented on Fasentra®.
    - Katie Rocawich, PharmD from Amgen presented on Tezspire®.
    - Alaina Gibson, PharmD from Sanofi presented on Dupixent®.
    - Dana Canning, RPh from GSK presented on Nucala™.
  - There were no questions for the speakers.
  - Asthma
    - Adding Dupixent® (dupilumab), Fasentra® (benralizumab), and Xolair® (omalizumab) as preferred with clinical criteria applied.
    - Adding Nucala™ (mepolizumab), Tezspire® (Tezepelumab-ekko) as non-preferred with clinical criteria applied.
  - Prurigo Nodularis
    - Adding Dupixent® (dupilumab) as preferred with clinical criteria applied.
  - Rhinosinusitis with Nasal Polyposis
    - Adding Dupixent® (dupilumab) and Xolair® (omalizumab) as preferred with clinical criteria applied.
    - Nucala™ (mepolizumab) as non-preferred with clinical criteria applied.
  - Chronic Spontaneous Urticaria
    - Adding Xolair® (omalizumab) as preferred with clinical criteria applied.

- Eosinophilic Esophagitis
  - Adding Dupixent® (dupilumab) as preferred with clinical criteria applied.
- IGE Mediated Food Allergy
  - Adding Xolair® (omalizumab) as preferred with clinical criteria applied.
- Eosinophilic Granulomatosis with Polyangitis
  - Adding Fasenra® (benralizumab) as preferred with clinical criteria applied.
  - Adding Nucala™ (mepolizumab) as non-preferred with clinical criteria applied.
- Hypereosinophilic Syndrome
  - Adding Nucala™ (mepolizumab) as preferred with clinical criteria applied.
- Duncan Norton, MD motioned for it to be approved, and Garrett Whittle, PharmD seconded the motion for approval. This change was approved unanimously.
- Sickle Cell Oral
  - Speaker:
    - Jalal Nait Hammoud, PharmD from Medunik USA presented on Siklos®.
  - There were no questions for the speaker.
    - Adding Droxia™ (hydroxycarbamide), Hydroxyurea capsules/powder, Siklos® (hydroxyurea), and Endari™ (L-glutamine) as preferred. Clinical criteria will be applied to Endari™.
  - Duncan Norton, MD motioned for this to be approved, and Patricia Witherspoon, MD seconded the motion for approval. This change was approved unanimously.
- Ophthalmic Antibiotics and Combination Products
  - No speaker/presenter.
  - Ophthalmic Antibiotics, Other:
    - Adding Bacitracin, Bacitracin-polymyxin B solution/ointment, Neomycin-bacitracin-polymyxin ointment, Neomycin-

- polymyxin-gramicidin, Polymyxin B-trimethoprim solution, and Sulfacetamide solution/ointment as preferred.
        - Adding Bleph 10 solution, Neosporin solution/ointment, and Polytrim solution as non-preferred.
      - Ophthalmic Antibiotics, Combinations
        - Adding Neomycin-bacitracin-poly B-hydrocortisone, Neomycin-polymyxin B- dexamethasone, Neomycin-polymyxin B- hydrocortisone, Prednisolone-gatifloxacin-bromfenac, Prednisolone-gatifloxacin-nepafenac, Prednisolone-gatifloxacin-bromfenac, Prednisolone-moxifloxacin-bromfenac, Prednisolone-moxifloxacin-nepafenac, Sulfacetamide-prednisolone, and Tobramycin-dexamethasone suspension as preferred.
        - Adding Blephamide, Blephamide S.O.P, Cortisporin, Gatifloxacin-dexamethasone PF drops, Maxitrol suspension/ointment, Poly-Pred, Pred-G suspension/ointment, Tobradex ointment, Tobradex ST suspension, and Zylet suspension as non-preferred.
      - Duncan Norton, MD motioned for it to be approved, and Garrett Whittle, PharmD seconded the motion for approval. This change was approved unanimously.

IX. Drug Classes for Re-Review ..... Manisa Bulsara, PharmD

- Ophthalmic Quinolones and Macrolides
  - No speaker/presenter.
    - Adding Erythromycin ointment/solution, Gentamicin drops/ointment, Moxifloxacin solution (generic for Moxeza<sup>®</sup>, Vigamox<sup>®</sup>), and Ofloxacin drops (generic for Ocuflax<sup>®</sup>) as preferred.
    - Adding Garamycin drops/ointment, Levofloxacin drops and Vigamox<sup>®</sup> drops as non-preferred.
  - Duncan Norton, MD motioned for it to be approved, and Garrett Whittle, PharmD seconded the motion for approval. This change was approved unanimously.
- COPD Agents, Inhaled and Oral
  - No speaker/presenter.
    - Adding Ipratropium nebulizer solution (generic for Atrovent<sup>®</sup>) and Ipratropium-albuterol solution (generic for Duoneb<sup>®</sup>) as preferred.
  - Duncan Norton, MD motioned for it to be approved, and Garrett Whittle, PharmD seconded the motion for approval. This change was approved unanimously.

- Gastrointestinal Antimicrobials
  - Adding clinical criteria to Xifaxan®.
  - Requiring a trial and failure of only 1 preferred product for non-preferred agents.
  - Duncan Norton, MD motioned for it to be approved, and Garrett Whittle, PharmD seconded the motion for approval.
  - Divya Ahuja, MD expressed concern and recommended moving Dificid from non-preferred to a preferred product to be aligned with ISDA and AGA guidelines. State representatives stated they will evaluate utilization of Dificid and will report back.
  - Duncan Norton, MD motioned for his approval to be amended for the inclusion of Dificid being preferred and Garrett Whittle, PharmD seconded the motion for approval. This change was approved unanimously.
  - On 11/19/2024, the state has reviewed and approved the amendment to move Dificid to preferred. Dr. Bulsara will provide and review utilization at an upcoming P&T Meeting.
  
- Electrolyte Modifiers
  - No speaker/presenter.
    - Adding Sodium polystyrene sulfonate, Lokelma®, and Veltassa® as preferred.
  - Duncan Norton, MD motioned for it to be approved, and Garrett Whittle, PharmD seconded the motion for approval. This change was approved unanimously.

- X. Brand to Generic..... Manisa Bulsara, PharmD
- Effective 1/1/2025 Amphetamine salt combo XR (generic for Adderall XR®) and methylphenidate ER (generic for Concerta®) will be preferred. Brand Adderall XR® and Concerta® will be moved to non-preferred. This change will align with MCO utilization.

- XI. Housekeeping.....Manisa Bulsara, PharmD
- Effective dates for Brand/Generic and Diabetic supplies changes will be January 1, 2025
  - All other categories discussed will be effective April 1, 2025.
  - New mailbox: [scpharma@primetherapeutics.com](mailto:scpharma@primetherapeutics.com)

- XII. Next P&T Meeting will be held on Wednesday, February 5, 2025, at 4pm.
- All P&T Committee members are encouraged to attend in person.
- XIII. Adjournment
- Meeting adjourned at 5:44pm.